Sarda Proteins

  • Market Cap: Small Cap
  • Industry: Edible Oil
  • ISIN: INE995U01011
  • NSEID:
  • BSEID: 519242
INR
93.13
0.00 (0.00%)
BSENSE

Jun 15

BSE+NSE Vol: 500

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

93.1393.13

52 Week

59.95137.45
Valuation
Technical
Day's Volume

CASH

500 (400.00%) Volume

Shareholding (Apr 2026)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

0.00%

Is Sarda Proteins overvalued or undervalued?

09-Jun-2025

As of January 6, 2025, Sarda Proteins Ltd. is considered overvalued with a "risky" rating due to high financial ratios, including a PE Ratio of 22.60 and a Price to Book Value of 9.54, despite a strong 1-year return of 62.51%.

As of 6 January 2025, Sarda Proteins Ltd. has moved from a grade of "does not qualify" to "risky," indicating a shift in its valuation outlook. The company appears to be overvalued based on its current financial ratios. The PE Ratio stands at 22.60, while the Price to Book Value is significantly high at 9.54, and the EV to Sales ratio is 21.29, all suggesting that the stock price may not be justified by its earnings or asset value.<BR><BR>In comparison to its peers, Sarda Proteins' PE ratio is higher than the industry average, which raises concerns about its valuation. Notably, its EV to EBITDA is -22.57, indicating negative earnings before interest, taxes, depreciation, and amortization, which is a significant red flag. While the company has outperformed the Sensex with a 1-year return of 62.51% compared to the Sensex's 7.57%, this performance may not be sustainable given the current valuation metrics. Overall, Sarda Proteins appears to be overvalued in the current market environment.

Read More

What is the technical trend for Sarda Proteins?

09-Jun-2025

As of May 20, 2025, Sarda Proteins shows a mildly bullish trend with mixed signals from indicators like the MACD, Bollinger Bands, and RSI, suggesting caution despite the current price being at a 52-week high of 137.45.

As of 20 May 2025, the technical trend for Sarda Proteins has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly RSI shows bearish momentum. Daily moving averages remain bullish, supporting the current price of 137.45, which is at a 52-week high. The KST is mildly bearish on a weekly basis but bullish monthly, and Dow Theory reflects a mildly bullish outlook in both time frames. Overall, the strength of the bullish trend is tempered by mixed signals in the RSI and KST, suggesting caution despite the positive indicators.

Read More

When is the next results date for Sarda Proteins?

27-Nov-2025

The next results date for Sarda Proteins is 29 November 2025.

The next results date for Sarda Proteins is scheduled for 29 November 2025.

Read More

How has been the historical performance of Sarda Proteins?

01-Dec-2025

Sarda Proteins has shown significant sales growth, with net sales rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, but faced challenges with increased expenditures, resulting in marginal operating profit and a decrease in profit after tax and EPS. Overall, while sales and total assets have grown, profitability remains a concern.

Answer:<BR>The historical performance of Sarda Proteins shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Sarda Proteins experienced a notable increase in net sales, rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, following a trend of varying sales figures over the previous years. The total operating income also reflected this growth, reaching 24.19 Cr in Mar'25 compared to 1.30 Cr in the prior year. However, the company faced challenges with total expenditure, which increased to 24.17 Cr in Mar'25 from 1.44 Cr in Mar'24. This resulted in a marginal operating profit of 0.02 Cr in Mar'25, a slight improvement from the losses recorded in earlier years. The profit before tax remained stable at 0.02 Cr for both Mar'25 and Mar'24, while profit after tax showed a decrease to 0.01 Cr in Mar'25 from 0.02 Cr in Mar'24. The earnings per share (EPS) also reflected this trend, decreasing to 0.06 in Mar'25 from 0.12 in Mar'24. On the balance sheet, total assets increased to 2.53 Cr in Mar'25 from 2.30 Cr in Mar'24, driven by a rise in short-term loans and advances. Overall, while Sarda Proteins has shown growth in sales and total assets, profitability metrics indicate ongoing challenges.

Read More

Should I buy, sell or hold Sarda Proteins?

02-Dec-2025

Which are the latest news on Sarda Proteins?

03-Dec-2025
How has been the historical performance of Sarda Proteins?
Sarda Proteins Faces Intense Selling Pressure Amidst Consecutive Gains

Why is Sarda Proteins falling/rising?

03-Dec-2025

As of 03-Dec, Sarda Proteins Ltd's stock price is at 80.20, showing no change from the previous session. The stock is underperforming with declining investor participation and significant financial weaknesses, indicating potential downward pressure.

As of 03-Dec, Sarda Proteins Ltd's stock price is currently at 80.20, showing no change from the previous trading session. The stock has recently experienced a trend reversal, having fallen after six consecutive days of gains. Today, the stock underperformed its sector by 4.42%, indicating a decline in performance relative to its peers. <BR><BR>The stock reached an intraday high of Rs 88.64, which represents a 5% increase, but it also touched an intraday low of Rs 80.20, reflecting a 5% decrease. This wide trading range of Rs 8.44 and high volatility, with an intraday volatility of 5%, suggest that the stock is experiencing significant fluctuations in price.<BR><BR>Investor participation appears to be declining, as evidenced by a 44.1% drop in delivery volume compared to the five-day average. This decrease in trading activity may contribute to the stock's current price stagnation and potential downward pressure. <BR><BR>Furthermore, the company faces long-term challenges, including a weak compound annual growth rate (CAGR) of -6.89% in operating profits over the last five years and a negative EBITDA, which indicates that the stock is trading at a risky valuation compared to its historical performance. The company's ability to service its debt is also concerning, with a poor EBIT to interest ratio of -0.01 and a low return on equity of 3.34%. <BR><BR>Overall, these factors suggest that Sarda Proteins Ltd's stock is facing downward pressure due to declining investor participation, recent performance trends, and underlying financial weaknesses.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

Weak Long Term Fundamental Strength with a -6.89% CAGR growth in Operating Profits over the last 5 years

  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.01
  • The company has been able to generate a Return on Equity (avg) of 3.34% signifying low profitability per unit of shareholders funds
2

Risky - Negative EBITDA

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Edible Oil

stock-summary
Market cap

INR 84 Cr (Small Cap)

stock-summary
P/E

133.00

stock-summary
Industry P/E

21

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.01

stock-summary
Return on Equity

1.75%

stock-summary
Price to Book

27.77

Revenue and Profits:
Net Sales:
1 Cr
(Quarterly Results - Mar 2026)
Net Profit:
1 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.59%
0%
27.59%
6 Months
13.42%
0%
13.42%
1 Year
-32.24%
0%
-32.24%
2 Years
4.88%
0%
4.88%
3 Years
102.32%
0%
102.32%
4 Years
243.65%
0%
243.65%
5 Years
166.47%
0%
166.47%

Sarda Proteins for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News
Sarda Proteins Ltd Valuation Shifts Signal Heightened Risk Amid Strong Sell Rating

Sarda Proteins Ltd Valuation Shifts Signal Heightened Risk Amid Strong Sell Rating

Sarda Proteins Ltd, a micro-cap player in the edible oil sector, has witnessed a significant shift in its valuation parameters, prompting a reassessment of its price attractiveness. Despite a robust five-year return of 350.56%, the company’s current price-to-earnings (P/E) and price-to-book value (P/BV) ratios have surged to levels that challenge traditional valuation norms, raising concerns among investors and analysts alike.

Read More

When is the next results date for Sarda Proteins Ltd?

The next results date for Sarda Proteins Ltd is scheduled for April 30, 2026....

Read More
Sarda Proteins Ltd is Rated Strong Sell

Sarda Proteins Ltd is Rated Strong Sell

Sarda Proteins Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are current as of 21 April 2026, providing investors with the latest view of the company’s performance and prospects.

Read More
Announcements stock-summary

Pre-Offer Advertisement cum corrigendum to Public Announcement Detailed Public Statement & Draft Letter of Offer

11-Jun-2026 | Source : BSE

Grow House Wealth Management Pvt Ltd (Manager to the Offer) has submitted to BSE a copy of Pre-Offer Advertisement cum corrigendum to the Public Announcement Detailed Public Statement and Draft Letter of Offer to the Public Shareholders of Sarda Proteins Ltd (Target Company).

Recommendations of Committee of Independent Directors (IDC)

08-Jun-2026 | Source : BSE

Independent Directors Committee (IDC) have submitted to BSE recommendations under Regulation 26(7) of SEBI (SAST) Regulations 2011 for the Open Offer to Public Shareholders of Sarda Proteins Ltd (Target Company)

Letter of Offer

04-Jun-2026 | Source : BSE

Grow House Wealth Management Pvt Ltd (Manager to the Offer) has submitted to BSE a copy of Letter of Offer to the Public Shareholders of the Sarda Proteins Ltd (Target Company).

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.87%
EBIT Growth (5y)
2.29%
EBIT to Interest (avg)
0.07
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-2.44
Sales to Capital Employed (avg)
5.16
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-2.02%
ROE (avg)
8.81%
Valuation key factors
Factor
Value
P/E Ratio
133
Industry P/E
21
Price to Book Value
27.77
EV to EBIT
76.24
EV to EBITDA
76.24
EV to Capital Employed
-17.57
EV to Sales
4.72
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
20.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Apr 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Ritika Vegetable Oil Private Limited (0.0%)

Highest Public shareholder

Onix Renewable Limited (77.99%)

Individual Investors Holdings

20.31%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 160.00% vs -94.19% in Dec 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 800.00% vs -130.00% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.65",
          "val2": "0.25",
          "chgp": "160.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.60",
          "val2": "-0.12",
          "chgp": "600.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.84",
          "val2": "-0.12",
          "chgp": "800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "92.31%",
          "val2": "-48.00%",
          "chgp": "140.31%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 10,800.00% vs -41.67% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -400.00% vs 400.00% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.26",
          "val2": "0.14",
          "chgp": "10,800.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.19",
          "val2": "0.02",
          "chgp": "-1,050.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.09",
          "val2": "0.03",
          "chgp": "-400.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1.25%",
          "val2": "14.29%",
          "chgp": "-15.54%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -35.88% vs 1,850.81% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -261.54% vs 0.00% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.51",
          "val2": "24.19",
          "chgp": "-35.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.31",
          "val2": "0.12",
          "chgp": "-358.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.21",
          "val2": "0.13",
          "chgp": "-261.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2.00%",
          "val2": "0.50%",
          "chgp": "-2.50%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is -33.20% vs 1,760.77% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 6,300.00% vs -50.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16.16",
          "val2": "24.19",
          "chgp": "-33.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.29",
          "val2": "0.02",
          "chgp": "1,350.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.64",
          "val2": "0.01",
          "chgp": "6,300.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "1.79%",
          "val2": "0.08%",
          "chgp": "1.71%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQstock-summary
Mar'26
Dec'25
Change(%)
Net Sales
0.65
0.25
160.00%
Operating Profit (PBDIT) excl Other Income
0.60
-0.12
600.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
0.84
-0.12
800.00%
Operating Profit Margin (Excl OI)
92.31%
-48.00%
140.31%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is 160.00% vs -94.19% in Dec 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 800.00% vs -130.00% in Dec 2025

All Quarterly Resultsstock-summary
Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary
Sep'25
Sep'24
Change(%)
Net Sales
15.26
0.14
10,800.00%
Operating Profit (PBDIT) excl Other Income
-0.19
0.02
-1,050.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.09
0.03
-400.00%
Operating Profit Margin (Excl OI)
-1.25%
14.29%
-15.54%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 10,800.00% vs -41.67% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is -400.00% vs 400.00% in Sep 2024

All Half Yearly Resultsstock-summary
Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary
Dec'25
Dec'24
Change(%)
Net Sales
15.51
24.19
-35.88%
Operating Profit (PBDIT) excl Other Income
-0.31
0.12
-358.33%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
-0.21
0.13
-261.54%
Operating Profit Margin (Excl OI)
-2.00%
0.50%
-2.50%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is -35.88% vs 1,850.81% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -261.54% vs 0.00% in Dec 2024

All Nine Monthly Resultsstock-summary
Annual Results Snapshot (Standalone) - Mar'26stock-summary
Mar'26
Mar'25
Change(%)
Net Sales
16.16
24.19
-33.20%
Operating Profit (PBDIT) excl Other Income
0.29
0.02
1,350.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
0.64
0.01
6,300.00%
Operating Profit Margin (Excl OI)
1.79%
0.08%
1.71%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is -33.20% vs 1,760.77% in Mar 2025

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2026 is 6,300.00% vs -50.00% in Mar 2025

All Annual Resultsstock-summary
stock-summaryCompany CV
About Sarda Proteins Ltd stock-summary
stock-summary
Sarda Proteins Ltd
Small Cap
Edible Oil
Sarda Proteins Ltd was incorporated in December 03, 1991. The company is mainly engaged in the distribution of refined oil, mustard oil and trading of Agro products like wheat, sesame seed, mustard seed, Guar seed and other edible products backed up with strong distribution network.The company had an opening paid up capital as on 1st April 2015 Rs. 2,43,48,500. The company issued a final notice during the year 2015-16 to holders of 16,96,500 partly paid shares of Rs.
Company Coordinates stock-summary
Company Details
B-536-537, Matsya Industrial Area Alwar Rajasthan : 301030
stock-summary
Tel: 91-144-2881392
stock-summary
http://www.sardaproteins.com
stock-summary
sardaproteins@yahoo.com
Registrar Details
Link Intime India Pvt Ltd., Narang Tower 44, Community Centre, Naraina Industrial Area , Phase - 1, New Delhi
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support.ra@mojomarkets.in, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."